Trump Administration Impact on the Global Fund: Fact Sheet

The Trump administration’s review of foreign aid has placed U.S. support for the Global Fund to Fight AIDS, Tuberculosis and Malaria under scrutiny, according to a KFF analysis published August 6, 2026. The review examines the funding levels and strategic direction of U.S. contributions to the partnership, which serves as a primary financing mechanism for infectious disease programs in low- and middle-income countries.

The Global Fund operates as a partnership between governments, civil society, and the private sector. According to KFF, the U.S. government is the largest donor to the fund, providing a significant portion of the capital used to scale up antiretroviral therapy for HIV, distribute insecticide-treated nets for malaria, and implement diagnostic testing for tuberculosis.

The current administration’s review focuses on the efficiency of these expenditures and whether the funding aligns with current U.S. national security and health priorities. This process follows a broader pattern of reviewing international health commitments to ensure they meet specific performance benchmarks.

Impact on Infectious Disease Programming

Changes in funding levels for the Global Fund can directly affect the delivery of life-saving medicines. According to KFF, the fund’s programs are critical for managing three of the world’s deadliest infectious diseases: HIV/AIDS, tuberculosis (TB), and malaria.

For malaria, the fund finances the purchase and distribution of bed nets and rapid diagnostic tests. Reductions in these allocations can lead to increased transmission rates in endemic regions, particularly among children under five and pregnant women.

Tuberculosis efforts rely on the fund for the procurement of first- and second-line drugs. KFF notes that interruptions in TB funding can result in treatment gaps, which increase the risk of developing drug-resistant strains of the bacteria.

HIV/AIDS programming through the Global Fund focuses on expanding access to antiretroviral therapy (ART) and preventing mother-to-child transmission. The analysis indicates that stable funding is necessary to maintain the viral suppression levels achieved in participating countries.

Relationship with PEPFAR and U.S. Health Aid

The Global Fund works alongside the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), the largest commitment by any nation to address a single disease. While PEPFAR is a bilateral U.S. program, the Global Fund is a multilateral organization.

According to KFF, the two entities often coordinate to avoid duplication of services. However, a shift in how the U.S. allocates resources between bilateral programs like PEPFAR and multilateral funds like the Global Fund can change how health services are managed on the ground.

Bilateral aid allows the U.S. government more direct control over how funds are spent and which specific health outcomes are prioritized. Multilateral aid through the Global Fund utilizes a country-led model where national governments and local stakeholders determine their own funding requests based on local epidemiological data.

Funding Risks and Global Health Stability

The Global Fund relies on multi-year replenishment cycles to plan its interventions. KFF reports that uncertainty regarding U.S. contributions during a foreign aid review can create instability for the fund’s long-term planning.

If the U.S. reduces its pledge or delays payments, other donor nations may be pressured to fill the gap, or the fund may be forced to scale back services in high-burden countries. This volatility can disrupt the supply chain for essential medicines and the salaries of community health workers.

The review’s outcome will determine if the U.S. maintains its role as the lead financier of the Global Fund or if it pivots toward a more restricted funding model tied to specific, short-term metrics.